Virus-specific T-cell products administered
| Patient . | Viral target . | VST infusions, n . | Product(s) infused (RPT, same product on reinfusion) . | Shared HLA alleles between product and recipient, n . | Shared HLA alleles . | CD3 response to PepMix by intracellular flow cytometry (cytokine[s] assayed), % . | Tetramer-positive cells of total CD3+ T-cells (tetramer used), % . |
|---|---|---|---|---|---|---|---|
| 1 | CMV | 1 | SCTL-14-0010 | 1 | A0201 | N/A | 34.8 (A0201 NLV) |
| 2 | CMV | 2 | SCTL-14-0010, RPT | 1 | A0201 | N/A | 34.8 (A0201 NLV) |
| 3 | CMV | 1 | SCTL-17-0017 | 1 | A0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV) |
| 4 | CMV | 2 | SCTL-17-0017, RPT | 2 | A0201, 2402 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV), 3.9% (A2401 QYD) |
| 5 | CMV | 1 | SCTL-17-0016 | 3 | A0301; B0702; C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 6 | CMV | 1 | SCTL-17-0016 | 4 | A0301; B0702, 4403; C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 7 | CMV | 1 | SCTL-17-0017 | 1 | A0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV) |
| 8 | CMV | 2 | SCTL-17-0017, RPT | 1 | A0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV) |
| 9 | CMV | 2 | SCTL-14-0007, RPT | 2 | B0801; DRB1 0301 | 40.3 (IFN)† | N/A |
| 10 | CMV | 1 | SCTL-14-0008 | 1 | A2402 | 16.7 (IFN) | 5.8 (A2401 QYD) |
| 11 | CMV | 2 | SCTL 17-0015, RPT | 2 | B0801; DQB1 0501 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 12 | CMV | 1 | SCTL-17-0016 | 4 | A0301; B0702, 4403; C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 13 | CMV | 4 | SCTL-17-0015, RPT, SCTL-17-0016, SCTL-17-0017 | 1 | DRB1 0101*, [A0301; B0702; C0701 transplant donor only] | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN), first product; 69.0 (CD107), 8.0 (TNF), 16.0 (IFN), second product; 76.9 (CD107), 47.7 (TNF), 58.1 (IFN), third product* | 25.2 (B0702 TPR), second product only |
| 14 | CMV | 1 | SCTL-17-0016 | 2 | B0702; C0701 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 15 | CMV | 1 | SCTL-17-0015 | 2 | B0801; C0701 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 16 | CMV | 2 | SCTL-17-0017, SCTL-17-0018 | 2 (both products) | A0201; C0701 (first product), A0201; B5101 (second product) | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN), first infusion; 48.3 (CD107), 18.4 (IFN), 15.1 (TNF), second infusion | 80.7 (A0201 NLV), first product; 76.5 (A0201 NLV), second product |
| 17 | EBV | 1 | SCTL-17-0017 | 6 | A0201; B4402; C0501, DRB1 0401; DQB1 0201, 0301 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | N/A |
| 18 | CMV | 1 | SCTL-17-0017 | 3 | DRB1 0301, 0301; DQB1 0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | N/A |
| 19 | EBV | 1 | SCTL-18-0010 | 7 | A0101; B0801; C0701; DRB10301, 0301; DQB1 0201, 0201 | 76.5 (CD107), 25.5 (TNF), 27.9 (IFN) | N/A |
| 20 | CMV | 1 | SCTL-17-0018 | 2 | A0201; B5101 | 48.3 (CD107), 18.4 (IFN), 15.1 (TNF) | 76.5 (A0201 NLV) |
| 21 | CMV | 1 | SCTL 17-0015 | 2 | B0801; C0701 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 22 | CMV | 1 | SCTL-17-0016 | 3 | A0301; B0702, C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 23 | CMV | 1 | SCTL-17-0016 | 5 | A0301; B4403; C0401, 0702; DRB10701 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | N/A |
| 24 | EBV | 2 | SCTL-18-0015, RPT | 2 | B4402; DQB1 0301 | 73.0 (CD107), 43.4 (TNF), 54.0 (IFN) | N/A |
| 25 | CMV | 1 | SCTL-17-0015 | 2 | DRB1 0101; DQB1 0501 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 26 | CMV | 1 | SCTL-17-0018 | 2 | A0201; C0704 | 48.3 (CD107), 18.4 (IFN), 15.1 (TNF) | 76.5 (A0201 NLV) |
| 27 | CMV | 2 | SCTL-17-0016, RPT | 6 | B0702, 4403; C0401, 0702; DRB1 1501; DQB1 0602 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 28 | CMV | 1 | SCTL-17-0016 | 4 | B0702, C0702; DRB1 1501; DQB1 0602 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 29 | CMV | 1 | SCTL-19-0005 | 2 | A0201; DQB1 0301 | 72.0 (CD107), 55.1 (TNF), 64.1 (IFN) | 84.3 (A0201 NLV) |
| 30 | CMV | 1 | SCTL-19-0029 | 3 | DRB1 0701, 1101; DQB1 0301 | 67.3 (CD107), 39.4 (TNF), 31.5 (IFN) | N/A |
| Patient . | Viral target . | VST infusions, n . | Product(s) infused (RPT, same product on reinfusion) . | Shared HLA alleles between product and recipient, n . | Shared HLA alleles . | CD3 response to PepMix by intracellular flow cytometry (cytokine[s] assayed), % . | Tetramer-positive cells of total CD3+ T-cells (tetramer used), % . |
|---|---|---|---|---|---|---|---|
| 1 | CMV | 1 | SCTL-14-0010 | 1 | A0201 | N/A | 34.8 (A0201 NLV) |
| 2 | CMV | 2 | SCTL-14-0010, RPT | 1 | A0201 | N/A | 34.8 (A0201 NLV) |
| 3 | CMV | 1 | SCTL-17-0017 | 1 | A0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV) |
| 4 | CMV | 2 | SCTL-17-0017, RPT | 2 | A0201, 2402 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV), 3.9% (A2401 QYD) |
| 5 | CMV | 1 | SCTL-17-0016 | 3 | A0301; B0702; C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 6 | CMV | 1 | SCTL-17-0016 | 4 | A0301; B0702, 4403; C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 7 | CMV | 1 | SCTL-17-0017 | 1 | A0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV) |
| 8 | CMV | 2 | SCTL-17-0017, RPT | 1 | A0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | 80.7 (A0201 NLV) |
| 9 | CMV | 2 | SCTL-14-0007, RPT | 2 | B0801; DRB1 0301 | 40.3 (IFN)† | N/A |
| 10 | CMV | 1 | SCTL-14-0008 | 1 | A2402 | 16.7 (IFN) | 5.8 (A2401 QYD) |
| 11 | CMV | 2 | SCTL 17-0015, RPT | 2 | B0801; DQB1 0501 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 12 | CMV | 1 | SCTL-17-0016 | 4 | A0301; B0702, 4403; C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 13 | CMV | 4 | SCTL-17-0015, RPT, SCTL-17-0016, SCTL-17-0017 | 1 | DRB1 0101*, [A0301; B0702; C0701 transplant donor only] | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN), first product; 69.0 (CD107), 8.0 (TNF), 16.0 (IFN), second product; 76.9 (CD107), 47.7 (TNF), 58.1 (IFN), third product* | 25.2 (B0702 TPR), second product only |
| 14 | CMV | 1 | SCTL-17-0016 | 2 | B0702; C0701 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 15 | CMV | 1 | SCTL-17-0015 | 2 | B0801; C0701 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 16 | CMV | 2 | SCTL-17-0017, SCTL-17-0018 | 2 (both products) | A0201; C0701 (first product), A0201; B5101 (second product) | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN), first infusion; 48.3 (CD107), 18.4 (IFN), 15.1 (TNF), second infusion | 80.7 (A0201 NLV), first product; 76.5 (A0201 NLV), second product |
| 17 | EBV | 1 | SCTL-17-0017 | 6 | A0201; B4402; C0501, DRB1 0401; DQB1 0201, 0301 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | N/A |
| 18 | CMV | 1 | SCTL-17-0017 | 3 | DRB1 0301, 0301; DQB1 0201 | 76.9 (CD107), 47.7 (TNF), 58.1 (IFN) | N/A |
| 19 | EBV | 1 | SCTL-18-0010 | 7 | A0101; B0801; C0701; DRB10301, 0301; DQB1 0201, 0201 | 76.5 (CD107), 25.5 (TNF), 27.9 (IFN) | N/A |
| 20 | CMV | 1 | SCTL-17-0018 | 2 | A0201; B5101 | 48.3 (CD107), 18.4 (IFN), 15.1 (TNF) | 76.5 (A0201 NLV) |
| 21 | CMV | 1 | SCTL 17-0015 | 2 | B0801; C0701 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 22 | CMV | 1 | SCTL-17-0016 | 3 | A0301; B0702, C0702 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 23 | CMV | 1 | SCTL-17-0016 | 5 | A0301; B4403; C0401, 0702; DRB10701 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | N/A |
| 24 | EBV | 2 | SCTL-18-0015, RPT | 2 | B4402; DQB1 0301 | 73.0 (CD107), 43.4 (TNF), 54.0 (IFN) | N/A |
| 25 | CMV | 1 | SCTL-17-0015 | 2 | DRB1 0101; DQB1 0501 | 32.9 (CD107), 30.9 (TNF), 26.7 (IFN) | N/A |
| 26 | CMV | 1 | SCTL-17-0018 | 2 | A0201; C0704 | 48.3 (CD107), 18.4 (IFN), 15.1 (TNF) | 76.5 (A0201 NLV) |
| 27 | CMV | 2 | SCTL-17-0016, RPT | 6 | B0702, 4403; C0401, 0702; DRB1 1501; DQB1 0602 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 28 | CMV | 1 | SCTL-17-0016 | 4 | B0702, C0702; DRB1 1501; DQB1 0602 | 69.0 (CD107), 8.0 (TNF), 16.0 (IFN) | 25.2 (B0702 TPR) |
| 29 | CMV | 1 | SCTL-19-0005 | 2 | A0201; DQB1 0301 | 72.0 (CD107), 55.1 (TNF), 64.1 (IFN) | 84.3 (A0201 NLV) |
| 30 | CMV | 1 | SCTL-19-0029 | 3 | DRB1 0701, 1101; DQB1 0301 | 67.3 (CD107), 39.4 (TNF), 31.5 (IFN) | N/A |
Not all products had available MHC class I tetramers for specificity testing.
TNF, tumor necrosis factor; IFN, interferon gamma.
This patient received 3 different products over 4 infusions. The first was matched at DRB1; the second at A0301 and B0702, but with the transplant donor only (not the recipient); and the third at C0701 (transplant donor only). Accordingly, for the third product used (matched at C0701), there was no available peptide for specificity testing.
Only CD4+ T-cells were tested for this product; CD4+ T-cells comprised 69.3% of total nucleated cells.